| RADIOLIGAND BINDING TO ANTI-DLL3 ANTIBODIES FOR PRETARGETED PET IMAGING AND THERAPEUTIC USES THEREOF JT Poirier, C Rudin, J Lewis, A Khan, D Andrew, X Chen, IC Lorenz, ... US Patent App. 18/589,649, 2024 | | 2024 |
| Examination of the PET in vivo generator 134Ce as a theranostic match for 225Ac D Bauer, R De Gregorio, EC Pratt, A Bell, A Michel, JS Lewis European Journal of Nuclear Medicine and Molecular Imaging, 1-11, 2024 | | 2024 |
| [225Ac] Ac-Isatuximab for CD38-targeted Theranostics in a Preclinical Model of Disseminated Multiple Myeloma NH Alvarez, D Bauer, A Michel, J Lewis Journal of Nuclear Medicine 65 (supplement 2), 241224-241224, 2024 | | 2024 |
| Recent advances and impending challenges for the radiopharmaceutical sciences in oncology SE Lapi, PJH Scott, AM Scott, AD Windhorst, BM Zeglis, M Abdel-Wahab, ... The Lancet Oncology 25 (6), e236-e249, 2024 | 1 | 2024 |
| Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics AM Scott, BM Zeglis, SE Lapi, PJH Scott, AD Windhorst, M Abdel-Wahab, ... The Lancet Oncology 25 (6), e250-e259, 2024 | | 2024 |
| CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer C Imberti, R De Gregorio, JA Korsen, TT Hoang, S Khitrov, T Kalidindi, ... Journal of Nuclear Medicine, 2024 | | 2024 |
| Radiolabeled ligands for targeted pet/spect imaging and methods of their use JS Lewis, D Demoin, YK Reshetnyak, OA Andreev, N Viola-villegas US Patent App. 18/353,822, 2024 | | 2024 |
| 18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer SL Cytryn, N Pandit-Taskar, MA Lumish, SB Maron, P Gu, GY Ku, JF Chou, ... Journal of Nuclear Medicine 65 (5), 722-727, 2024 | | 2024 |
| Dietary intake and glutamine-serine metabolism control pathologic vascular stiffness NS Rachedi, Y Tang, YY Tai, J Zhao, C Chauvet, J Grynblat, ... Cell Metabolism, 2024 | | 2024 |
| Antibody-pyrrolobenzodiazepine derivative conjugate JT Poirier, C Rudin, J Lewis, A Khan, D Andrew, X Chen, I Lorenz, ... US Patent App. 18/272,049, 2024 | | 2024 |
| Anti-dll3 antibody-drug conjugate JT Poirier, C Rudin, J Lewis, A Khan, D Andrew, X Chen, I Lorenz, ... US Patent App. 18/272,050, 2024 | | 2024 |
| NaV1. 7 targeted fluorescence imaging agents for nerve identification during intraoperative procedures J Gonzales, D Adilbay, PD de Souza Franca, R Artschwager, CY Chow, ... bioRxiv, 2024 | 1 | 2024 |
| Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer KN Mack, ZV Samuels, LM Carter, TD Viray, K Mandleywala, CL Brooks, ... Journal of Nuclear Medicine 65 (4), 580-585, 2024 | 2 | 2024 |
| Copper-67 as a next-generation radioconjugate warhead for cancer therapy M Harris, K Gehlsen, L McInnes, J Lewis Cancer Research 84 (6_Supplement), 6037-6037, 2024 | | 2024 |
| Utilizing shortwave infrared fluorescence imaging (SWIRFI) for targeted preclinical tumor resection B Mc Larney, M Skubal, M Kim, J Lewis, D Heller, J Grimm Molecular-Guided Surgery: Molecules, Devices, and Applications X, PC128250L, 2024 | | 2024 |
| First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer R Yeh, JA O’Donoghue, VS Jayaprakasam, A Mauguen, R Min, S Park, ... Journal of Nuclear Medicine 65 (3), 386-393, 2024 | 3 | 2024 |
| Noninvasive assessment of programmed-death ligand-1 (PD-L1) in esophagogastric (EG) cancer using 18F-BMS-986229 PET. SL Cytryn, N Pandit-Taskar, SB Maron, P Gu, GY Ku, JF Chou, M Capanu, ... Journal of Clinical Oncology 42 (3_suppl), 409-409, 2024 | | 2024 |
| First-in-human imaging with [89Zr] Zr-DFO-SC16. 56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate S Tendler, MP Dunphy, M Agee, J O’Donoghue, RG Aly, NJ Choudhury, ... medRxiv, 2024 | | 2024 |
| Correction to “Shifting the Antibody–Drug Conjugate Paradigm: A Trastuzumab-Gold-Based Conjugate Demonstrates High Efficacy against Human Epidermal Growth Factor Receptor 2 … A Ahad, HK Saeed, V Del Solar, JE López-Hernández, A Michel, ... ACS Pharmacology & Translational Science 7 (1), 298-299, 2024 | | 2024 |
| Exploring the PET in vivo generator 134Ce as a theranostic match for 225Ac D Bauer, R De Gregorio, EC Pratt, A Bell, A Michel, JS Lewis bioRxiv, 2024 | | 2024 |
